pyrazines has been researched along with Lymphoma, Primary Effusion in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashlock, BM; Bhatt, S; Diaz, LA; Lossos, IS; Mesri, EA; Ramos, JC; Toomey, NL | 1 |
| Cirone, M; D'Orazi, G; Di Renzo, L; Faggioni, A; Frati, L; Garufi, A; Gonnella, R; Granato, M; Lotti, LV; Santarelli, R; Trivedi, P | 1 |
| Joyce, RM; Siddiqi, T | 1 |
| Bhatt, S; Blasini, W; Cavallin, LE; Gentles, AJ; Lossos, IS; Mesri, EA; Natkunam, Y; Ramos, JC; Sarosiek, KA; Toomey, NL | 1 |
| Cirone, M; Conte, V; Di Renzo, L; Faggioni, A; Frati, L; Gonnella, R; Lotti, LV; Santarelli, R; Trivedi, P | 1 |
| Boulanger, E; Meignin, V; Oksenhendler, E | 1 |
6 other study(ies) available for pyrazines and Lymphoma, Primary Effusion
| Article | Year |
|---|---|
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; HEK293 Cells; Herpesviridae Infections; Herpesvirus 8, Human; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lymphoma, Primary Effusion; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Tumor Suppressor Protein p53; Virus Latency; Virus Replication; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells.
Topics: Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Enzyme Activation; Gene Knockdown Techniques; Humans; Lymphoma, Primary Effusion; MAP Kinase Kinase 4; Microscopy, Electron; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Herpesviridae Infections; Herpesvirus 8, Human; HIV; Humans; Immunohistochemistry; Liposomes; Lymphoma, Primary Effusion; Male; Positron-Emission Tomography; Pyrazines; Rituximab | 2008 |
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.
Topics: Aged, 80 and over; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Chlorocebus aethiops; DNA Replication; Down-Regulation; E2F3 Transcription Factor; Fatal Outcome; Gene Expression Regulation, Neoplastic; Herpesvirus 8, Human; Humans; Lymphoma, Primary Effusion; Male; Mice; NF-kappa B; Proto-Oncogene Proteins c-myc; Pyrazines; Survival Analysis; Treatment Outcome; Unfolded Protein Response; Vero Cells; Virion; Xenograft Model Antitumor Assays | 2010 |
Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Calreticulin; Cell Line; Dendritic Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Kinetics; Low Density Lipoprotein Receptor-Related Protein-1; Lymphoma, Primary Effusion; Phagocytosis; Protein Transport; Pyrazines; Tyrphostins | 2012 |
Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Herpesviridae Infections; Herpesvirus 8, Human; Humans; Lymphoma, AIDS-Related; Lymphoma, Primary Effusion; Male; Middle Aged; Pyrazines | 2008 |